Scynexis Inc (SCYX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Scynexis Inc stock (SCYX) is currently trading at $0.88. Scynexis Inc PS ratio (Price-to-Sales) is 1.90. Analyst consensus price target for SCYX is $3.47. WallStSmart rates SCYX as Underperform.
- SCYX PE ratio analysis and historical PE chart
- SCYX PS ratio (Price-to-Sales) history and trend
- SCYX intrinsic value — DCF, Graham Number, EPV models
- SCYX stock price prediction 2025 2026 2027 2028 2029 2030
- SCYX fair value vs current price
- SCYX insider transactions and insider buying
- Is SCYX undervalued or overvalued?
- Scynexis Inc financial analysis — revenue, earnings, cash flow
- SCYX Piotroski F-Score and Altman Z-Score
- SCYX analyst price target and Smart Rating
Scynexis Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Scynexis Inc (SCYX) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in operating margin, price/sales, price/book. Concerns around market cap and return on equity. Mixed signals suggest waiting for clearer direction before acting.
Scynexis Inc (SCYX) Key Strengths (4)
Keeps $56 of every $100 in revenue after operating costs
Trading below book value, meaning the market prices it less than net assets
Revenue surging 1809.00% year-over-year
Paying $1.90 for every $1 of annual revenue
Supporting Valuation Data
Scynexis Inc (SCYX) Areas to Watch (4)
Company is destroying shareholder value
Company is losing money with a negative profit margin
Micro-cap company with very limited liquidity and high volatility
Low institutional interest, mostly retail-driven
Scynexis Inc (SCYX) Detailed Analysis Report
Overall Assessment
This company scores 48/100 in our Smart Analysis, earning a D+ grade. Out of 8 metrics analyzed, 4 register as strengths (avg 9.5/10) while 4 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Operating Margin, Price/Book, Revenue Growth. Valuation metrics including Price/Sales (1.90), Price/Book (0.84) suggest the stock is attractively priced. Profitability is solid with Operating Margin at 56.40%. Growth metrics are encouraging with Revenue Growth at 1809.00%.
The Bear Case
The primary concerns are Return on Equity, Profit Margin, Market Cap. Profitability pressure is visible in Return on Equity at -16.50%, Profit Margin at -41.80%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -16.50% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 1809.00% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. Strengths and concerns are roughly balanced. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Profit Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
SCYX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
SCYX's Price-to-Sales ratio of 1.90x trades at a deep discount to its historical average of 5.84x (14th percentile). The current valuation is 83% below its historical high of 11.45x set in Mar 2026, and 5% above its historical low of 1.81x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~10.7x as trailing revenue scaled faster than the stock price.
Compare SCYX with Competitors
Top DRUG MANUFACTURERS - SPECIALTY & GENERIC stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Scynexis Inc (SCYX) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
Scynexis Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 21M with 1809% growth year-over-year. The company is currently unprofitable, posting a -41.8% profit margin.
Key Findings
Revenue growing at 1809% YoY, reaching 21M. This pace significantly outperforms most DRUG MANUFACTURERS - SPECIALTY & GENERIC peers.
Generating 18M in free cash flow and 18M in operating cash flow. Earnings are translating into actual cash generation.
The company is unprofitable with a -41.8% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Growth sustainability: can Scynexis Inc maintain 1809%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact Scynexis Inc.
Bottom Line
Scynexis Inc is a high-conviction growth story with revenue accelerating at 1809% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -41.8% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Scynexis Inc(SCYX)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
SCYNEXIS, Inc., a biotechnology company, offers therapies for the treatment of yeast infections in the United States. The company is headquartered in Jersey City, New Jersey.